Only Apolipoprotein E polymorphisms have been consistently associated with the risk of late-onset Alzheimer disease (LOAD), but they represent only a minority of the underlying genetic effect. To identify additional LOAD risk loci, we performed a genome-wide association study (GWAS) on 492 LOAD cases and 498 cognitive controls using Illumina's HumanHap550 beadchip. An additional 238 cases and 220 controls were used as a validation data set for single-nucleotide polymorphisms (SNPs) that met genome-wide significance. To validate additional associated SNPs (p < 0.0001) and nominally associated candidate genes, we imputed SNPs from our GWAS using a previously published LOAD GWAS 1 and the IMPUTE program. Association testing was performed with the Cochran-Armitage trend test and logistic regression, and genome-wide significance was determined with the False Discovery Rate-Beta Uniform Mixture method. Extensive quality-control methods were performed at both the sample and the SNP level. The GWAS confirmed the known APOE association and identified association with a 12q13 locus at genome-wide significance; the 12q13 locus was confirmed in our validation data set. Four additional highly associated signals (1q42, 4q28, 6q14, 19q13) were replicated with the use of the imputed data set, and six candidate genes had SNPs with nominal association in both the GWAS and the joint imputated data set. These results help to further define the genetic architecture of LOAD.
Introduction
Alzheimer Disease (AD [MIM 104300]) is the leading cause of dementia in the elderly and has a complex etiology, with strong genetic and environmental determinants. Apolipoprotein E (APOE [MIM 107741]) is the single most significant genetic risk factor identified for late-onset AD (LOAD) and was identified as a risk gene primarily through genetic mapping. [2] [3] [4] [5] Though APOE has been universally confirmed as a risk gene for LOAD, the risk polymorphism is neither necessary nor sufficient to cause AD, given that as much as 50% of the genetic-risk effect remains unexplained. 6 Efforts to identify additional AD loci have primarily taken the form of genome-wide linkage scans in multiplex families (two or more individuals with AD) and candidate-gene association studies. Though linkage scans were instrumental in detecting the effect of the APOE gene, they suffer from low resolution (signals often cover over 30 million base pairs) and have low power to detect smaller signals. 7 Candidate-gene studies use increased resolution, but their ability to replicate positive results has been both difficult and inconsistent. 8 With the advent of genome-wide association studies (GWAS), we can now interrogate the entire genome with increased resolution and power. GWAS have already been completed for a variety of complex genetic diseases, with varying degrees of success. 1, [9] [10] [11] [12] [13] [14] [15] Two published GWAS have examined LOAD, and both studies 13, 14 convincingly confirmed the association of APOE to LOAD (p value ¼ 1.0 3 10 À39 and 2.3 3 10 À44 , respectively), but neither has shown genome-wide significance at any SNP unlinked to APOE. This suggests that the remaining LOAD risk loci must be of small effect.
To identify the loci underlying the remaining genotypic effect, we present here a GWAS of LOAD, with 492 cases and 498 controls, using the Illumina HumanHap 550 beadchip. SNPs significant at the genome-wide level were genotyped in an independent validation data set. SNPs with strong association (p values < 0.0001) and nominally associated SNPs (p values < 0.05) in and near candidate genes were examined in a previous GWAS of AD (by Reiman et al. 1 ) using an imputation procedure.
age. 17 Subjects' AAO for LOAD was determined from specific probe questions within the clinical history provided by a reliable family informant or from documented significant impairment in the medical record. Cognitive controls were spouses, friends, and other biologically unrelated individuals who were frequency matched by age and gender to the cases and were from within the same clinical catchment areas. Table 1 ). After genotyping and before the statistical analysis, samples had to pass a stringent set of quality control tests, so that the integrity of the genetic data was ensured. The final GWAS data set analyzed contains a total of 988 individuals of European descent. There are 492 LOAD cases, average age 72.9 years at onset (þ/À 6.6 years), and 496 cognitive controls, average age 74.3 years at exam (þ/À 6.5 years). Cases are 61% female, and controls are 63% female.
The validation data set consisted of 238 LOAD cases and 220 controls-independent of the preliminary cohort-that were subjected to the same inclusion criteria as those in the GWAS data set. The cases averaged 67.7 years AAO (þ/À 8.6 years), and the controls averaged 70.5 years age at exam (þ/À 6.5).
Genotyping
We extracted DNA for individuals ascertained by the CAP by using Puregene chemistry (QIAGEN, Germantown, MD, USA). We performed genotyping using the Illumina Beadstation and the Illumina HumanHap 550 beadchip, following the recommended conditions, with the exception that we required the more conservative gencall score of 0.25. Genotyping efficiency was greater than 99%, and quality assurance was achieved by the inclusion of two CEPH controls that were genotyped multiple times. The lab was blinded to affection status and quality-control samples. The ABI 7900 Taqman system was used for generating APOE genotypes corresponding to allele combinations at SNP þ3937/ rs429358 and SNP þ4075/rs7412.
Sample-Quality Control
After genotyping, samples were subjected to a battery of qualitycontrol tests. One measure of the overall quality of a sample's data is sample efficiency; the proportion of valid genotype calls to attempted calls within a sample. Samples with efficiency less than 0.98 were dropped from the analysis. Many of these samples were previously genotyped on the Illumina Goldengate and/or ABI Taqman platforms for SNPs that were in the GWAS (80% of samples were previously typed at 100 or more SNPs; average ¼ 346, median ¼ 428). This duplication validates that the sample was correctly acquisitioned and that the Infinium II assay was accurate. Samples with less than 90% genotype-concordance rates on 100 or more previously typed SNPs were dropped from the analysis. Reported gender and genetic gender were examined with the use of X-linked SNPs; inconsistent samples were dropped from the analysis. Relatedness between samples was tested via the program Graphical Representation of Relatedness (GRR), 19 and related samples were dropped from the analysis. A set of 3500 independent SNPs (not in strong linkage disequilibrium [LD], r 2 < 0.16) spread evenly across the autosomal chromosomes were analyzed in STRUCTURE 20 for evidence of population substructure (burn in: 1000, iterations: 20,000). In addition to this first run, we ran 250 SNPs with twice the number of iterations. We also used the program EigenStrat to look for population substructure. EigenStrat is a principle-components-analysis program that utilizes eigenvalues to investigate substructure and to potentially correct for it. 21 A set of 20,000 SNPs across the genome was used.
SNP-Quality Control
SNPs were subjected to several tests for quality before being analyzed. Genotypes were first recalled on the basis of our own data, per Illumina's recommendations. Recalling corrects missed calls due to ill-defined HapMap clusters and eliminates SNPs for which the platform is inconsistent. Only samples with efficiency greater than 0.98 were used for redefining the genotype clusters. SNP efficiency is calculated as the percentage of samples that have genotype calls for a given SNP. All SNPs with less than 90% efficiency were dropped from the analysis. SNPs with MAF < 0.005 were dropped, because even under highly optimistic conditions (high risk ratio, direct ascertainment of the disease locus), these SNPs have 50% power at best. To reduce error, we subjected SNPs with MAF < 0.10 to a more stringent efficiency cutoff of 99%. SNPs could have significant Hardy-Weinberg disequilibrium statistics for legitimate biological reasons and could have even been used for disease inference. 22, 23 Laboratory-process errors typically lead to very extreme disequilibrium, so SNPs were only dropped when the HWD statistic was significant at the p < 10 À6 level.
HWD statistics were calculated with the Fisher's exact test in the PLINK package. 24 
Association Analysis
Association analysis was performed with the use of the CochranArmitage trend test for association. 25 This method tests for a linear trend in the number of alleles at a single locus. That is, two copies of an allele have more of an effect than one copy, which in turn has more of an effect than no copies. The effect is in the same direction for each genotype. This test is equivalent to the score statistic from a logistic-regression model with no covariates. In addition to the standard trend test, we performed logistic regression, with APOE status, age at onset (cases) or exam (controls), and gender as covariates. All analyses were performed via PLINK.
24
APOE status was designated as the number of e4 alleles. A genomewide multiple-testing correction was applied with a false-discovery rate, with the use of the beta-uniform distribution. 26 SNPs with FDR q values less than 0.20 were declared significant. Initial haplotyping was performed with the Haploview software 27 using the confidence-interval-based block definitions, 28 and follow-up was performed with the Haplo.Stats software.
29,30
Imputation Analysis
The software IMPUTE 16 was used for imputing genotype data. Both our data and the data from the previous GWAS 1 were imputed, independently, to a HapMap reference of over 2.5 million SNPs. Individual genotypes with probability less than 0.90 were not included, and SNPs missing > 10% of genotypes within either data set were dropped from the joint analysis. Joint analysis was performed with PLINK. 24 Association testing was performed in PLINK, with logistic regression, with an indicator variable of study of origin included as a covariate.
Results
Genotypes were initially generated on 518 LOAD cases and 531 cognitive controls for 555,000 SNPs. Stringent qualitycontrol criteria were required for all samples and markers. Of the initial 1049 samples, 988 met the quality-control criteria (492 cases, 498 controls; average genotyping efficiency > 99.8%). There were 31 samples (3%) dropped because their efficiencies were less than 98%, and 17 samples were dropped because their concordance rates were less than 90%. Nine samples were dropped because the genotypic gender disagreed with the clinical information (five males that tested female, four females that tested male), and three samples were dropped because of their relatedness to other samples. One additional sample was dropped for clinical reasons. Of the 555,000 SNPs, only 23,000 (4%) were dropped from the analysis (average minor-allele frequency of the remaining SNPs ¼ 0.246). Samples were tested for population substructure, and none was found. In STRUCTURE, there were no samples that consistently clustered in the same groups and there was no observation of bimodality or outliers in the plots. In Eigenstrat, the top PCA components accounted for only a small percentage of variation (< 3%) and there was no bimodality or outliers in the plots of the top principal components. There were 38 SNPs with uncorrected p values < 0.00005 for association to LOAD using the Cochran-Armitage trend test, six of which were in or near the APOE gene (Table 2 ; complete results in Figure 1 ), including the top three (not shown). The LOAD association at APOE represents a positive control. The remaining 32 SNPs span the genome, representing 19 distinct signals across 16 chromosomes. There was little change in this list when logistic regression with covariates was applied instead of the trend test (sex, age at onset or at exam, and APOEe4-carrier status as covariates). The majority of these signals (12 of 19) lie in regions that have previously shown genetic linkage to LOAD through other studies. 8 The most significant non-APOE SNP was rs11610206 on 12q13 (45.92 Mb) . This SNP met genome-wide significance criteria with the use of the False Discovery Rate-Beta Uniform Mixture (FDR-BUM) 26 multiple-testing-correction criteria. The uncorrected p value was 1.93 3 10 À6 (FDR ¼ 0.17). Because this SNP met our significance criteria, we genotyped the marker in an independent data set. The marker was significant in our independent replication data set of 238 cases and 220 controls (p ¼ 0.0496). The association was in the same direction, and the joint analysis had a p value of 3.452 3 10 À7 , nearly an order of magnitude more significant than in the initial data set. There is some mild LD structure in this region, but a haplotype analysis of this and surrounding SNPs does not reveal any stronger association than that of the rs11610206 SNP alone. There are a number of genetic linkage results on 12q13. [31] [32] [33] [34] In particular, the broad linkage signals observed on 12q were narrowed considerably in the Liang et al. study 34 using an ordered-subset analysis (44 Mb-48 Mb). This association lies directly under the Liang et al. linkage signal and represents a confirmation of that signal in an independent data set; no individuals from the families in the Liang et al. study were used in our case-control cohort. Other than three of the APOE-linked SNPs, there were no additional loci that met the FDR threshold. To validate additional associated SNPs, we used an imputation approach. Both our GWAS and the previously published GWAS 1 were imputed to a HapMap reference with the use of IMPUTE, 16 and the common SNPs were the basis for comparison. We first compared the strongly associated results from each study (p < 0.0001), and we then examined nominally associated markers within known candidate genes.
Among the top signals in the GWAS, there were four that showed association in both studies ( leads to a missense mutation. The ZNF224 signal is 800 kb proximal to APOE but is not in LD to APOE (Table 4) . Additionally, logistic regression of our data showed that the association of the ZNF224 signal was not greatly diminished when APOEe4-carrier status was included as a covariate. The rs20612332 SNP has a p value equal to 0.000030 without APOEe4-carrier status as a covariate and a p value equal to 0.000038 with carrier status as a covariate. This confirms that the signal is independent of APOE.
The two other signals replicated in both data sets are not in known genes. The gene nearest the chromosome 6 signal is branched chain keto acid dehydrogenase E1, beta polypeptide (BCKDHB [MIM 248611]) but is over 800 kb proximal to the SNP. The chromosome 4 signal is 200 kb proximal to protocadherin 18 (PCDH18 [MIM 608287]), a protocadherin precursor that is thought to play a role in cell-cell connections in the brain.
In addition to these top hits, nine candidate genes from the over 500 genes in the AlzGene candidate-gene list 1 have SNPs with nominal association in both GWASs ( 
Discussion
We have shown genome-wide association of the SNP rs11610206 with LOAD and have validated this signal in an independent case-control data set. This provides strong evidence for a risk locus on 12q13. The SNP is not in a known gene but is less than 10 kb from the hypothetical gene FAM113B. Additionally, there are a number of nearby candidate genes, such as the vitamin D (1,25-dihydroxyvitamin D3) receptor (VDR [MIM 601769]) and adhesion molecule with Ig-like domain 2 (AMIGO2). VDR is the most appealing of the candidate genes. There has been association with VDR reported, 35 and VDR has been associated with memory performance. 36 There is no known connection between our top SNP and VDR, but the region between the two is largely uncharacterized; it is possible that the top SNP could be in a long-range regulatory element that influences VDR. It is of note that the rs11610206 SNP was not imputed in the Reiman 1 data with enough confidence to allow inclusion in the imputation analysis. This demonstrates one of the weaknesses of imputation. If there is not strong LD between a genotyped SNP and an untyped SNP of interest, the untyped SNP will not be imputed with high confidence. In this case, there is not extended LD around rs11610206, so the nearest SNPs in the Reiman GWAS were not sufficiently informative for imputation. This same phenomenon was seen at the APOE locus. The two data sets did not share any SNP near APOE, and nearby
HapMap SNPs were not imputed with confidence. In the end, the signal at APOE-highly significant in each individual GWAS-is missed entirely in the joint imputation analysis unless quality control standards are lowered. Indeed, nearly 20% of the top SNPs from our GWAS failed to be imputed in the Reiman data. Four of the top hits among the GWAS were validated in the imputation analysis. The 1q42 and 19q13 signals are of particular interest. The 1q42 signal resides in the DISC1 gene, a gene that has been associated with schizophrenia and has links to bipolar disorder, depression, and cognitive function. [37] [38] [39] [40] [41] The 19q13 signal lies in the exon of the ZNF224 gene, and several of the SNPs were coding SNPs, including one missense mutation. Although this is not the first report of a non-APOE signal on 19q13, 42, 43 it is the first time the ZNF224 gene has been implicated specifically. There were eight candidate genes from the AlzGene list with SNPs associated in both GWASs. Principal among these genes is sortlin-related receptor (SORL1), a gene that has received much attention in LOAD genetics. SORL1 (alternatively LR11 or SorLA) has been associated with LOAD in a variety of populations. [44] [45] [46] [47] Replication has been inconsistent, 45, 48, 49 and it is thought that there could be extensive locus and allelic heterogeneity involved. 44, 50 LD between the ZNF224 SNPs on 19q13 (rs4459653, rs4802207, rs3746319, rs2061332) and SNPs most linked to APOE on 19q13 (rs2075650, rs8106922, rs405509, rs439401). Disequilibrium is reported as r 2 . Position is reported in base pairs. This shows that there is a single ZNF224 signal that is independent from the APOE signal. There are also multiple studies that show that SORL1 expression is decreased in Alzheimer disease and in the cognitively impaired brain. [51] [52] [53] Although there are no consensus SORL1 mechanisms that confer LOAD risk, it is known that the SORL1 protein interacts with both APOE protein and amyloid beta (A4) precursor protein (APP [MIM 104760]). 44, 54 The findings of association in our GWAS, as well as in the joint analysis with the Reiman GWAS, further confirm SORL1 as a risk gene for LOAD. Also among the nominally associated genes are guanylate binding protein 2, interferon-inducible (GBP2), which is upregulated in the hippocampus in AD and has previously shown nominal significance to AD, 55 and the gene WW and C2 domain containing 1 (WWC1), which has shown association with AD in a Spanish population. 56 
WWC1
has also been associated with memory performance based on a verbal-memory task. 57 It is of note that multiple testing is an issue with the imputation analysis. There are many tests, because the imputation provides a dense map; this suggests a more stringent threshold. However, the tests are highly correlated as a result of LD, and there is a priori evidence for the candidate-gene SNPs, suggesting a more relaxed threshold. Rather than arbitrarily quantifying a statistical prior or establishing a highly arbitrary significance threshold, we report uncorrected p values and look for concordance between the two GWAS.
We have shown a genome-wide significant association between the 12q13 SNP rs11610206 and late-onset Alzheimer disease. This signal was replicated in an independent case-control cohort. The region around this SNP is largely uncharacterized, and further delineation of possible candidates near this SNP is needed. We have also identified four regions (1q42, 4q28, 6q14, 19q13) with strong association to AD that were replicated in the imputation analysis, confirmed the association of SORL1 to LOAD, and validated a number of candidate genes with nominal association in both GWAS. Detailed functional examination of these signals and genes could lead to a better understanding of the complex pathophysiology of Alzheimer disease. Aging (grants AG20135 and AG19757) and the National Institute of Neurological Disorders and Stroke (grant NS31153), both of the National Institutes of Health; the Alzheimer's Association; and the Louis D. Scientific Award of the Institut de France. A subset of the participants was ascertained while M.A.P.-V. was a faculty member at Duke University. 
